Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 12
Submit an article Journal homepage
1,854
Views
1
CrossRef citations to date
0
Altmetric
Reviews

Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL

William G. Wierdaa University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
View further author information
,
Thomas J. Kippsb UCSD Moores Cancer Center, San Diego, CA, USAView further author information
,
Othman Al-Sawafc Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Düsseldorf, German CLL Study Group, University Hospital, University of Cologne, Cologne, GermanyView further author information
,
Brenda Chylad AbbVie Inc., North Chicago, IL, USAView further author information
,
Juliana M. L. Biondoe Genentech, Inc., South San Francisco, CA, USAView further author information
,
Yong Mune Genentech, Inc., South San Francisco, CA, USAView further author information
,
Yanwen Jiange Genentech, Inc., South San Francisco, CA, USAView further author information
&
John F. Seymourf Peter MacCallum Cancer Centre, Royal Melbourne Hospital & University of Melbourne, Melbourne, VIC, AustraliaView further author information
 show all
Pages 2765-2784 | Received 27 May 2022, Accepted 27 Jun 2022, Published online: 19 Aug 2022

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.